Stay up to date on the latest oncology and nursing conferences.
Assessing Subsequent Therapies in mHSPC Confirms OS Benefit From Darolutamide
February 4th 2024Subsequent therapies in patients with metastatic hormone-sensitive prostate cancer who were censored from primary overall survival follow-up from the ARASENS trial, according to a post hoc sensitivity analysis, confirmed the overall survival benefit derived from darolutamide plus androgen deprivation therapy and docetaxel.
Abiraterone Plus Prednisone, Apalutamide Improves Prostate Cancer Outcomes Without Impacting HRQoL
January 31st 2024After radical prostatectomy, patients with prostate cancer treated with abiraterone acetate plus prednisone and apalutamide had improved outcomes without a significant impact on their health-related quality of life.
Nivolumab Plus Ipilimumab Significantly Improves PFS in mCRC
January 30th 2024First-line treatment with nivolumab plus ipilimumab for patients with microsatellite instability–high or mismatch repair deficient metastatic colorectal cancer can be considered a standard-of-care option based on results from the phase 3 CheckMate-8HW trial.
Darolutamide With ADT Before Surgery May Be Safe, Effective in Prostate Cancer
January 28th 2024Researchers did not observe any grade 3 or 4 adverse events with darolutamide with androgen deprivation therapy for 6 months followed by radical prostatectomy in patients with locally advanced prostate cancer.
High-Dose Radiation, Long-Term ADT May Be Standard for High-Risk Prostate Cancer
January 26th 2024Patients with high-risk prostate cancer treated with a higher dose of radiation therapy and long-term androgen deprivation therapy improved progression-free, cancer-specific, and overall survival compared with the standard dose of radiation.
Firstline Olaparib-Based Treatment Improves PFS, Responses in mCRPC
January 26th 2024Frontline olaparib plus abiraterone/prednisone improved progression-free survival and responses in patients with metastatic castration-resistant prostate cancer compared with each of the components of the therapy alone.
ERBT Before Ra-223 May Not Increase Hematological Toxicity in mCRPC
January 26th 2024Patients with metastatic castration-resistant prostate cancer who were previously treated with external beam radiation therapy before radium-223 did not experience an increase in hematological toxicity compared with the overall population.
Standard-of-Care HRRm Testing Underutilized in Patients With mCRPC
January 25th 2024Despite germline and somatic testing being the standard of care for patients with metastatic castration-resistant prostate cancer, rates of its real-world use shows that it may be underutilized, which may negatively impact therapeutic offerings.
Darolutamide Plus ADT May Lower Hospitalization Rates, Slightly Prolong Stays in mHSPC
January 25th 2024Darolutamide plus androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer may lower hospitalization rates but marginally longer lengths of stay vs treatment with placebo, androgen deprivation therapy, and docetaxel.
Adding Pembrolizumab to Lenvatinib Shows ‘Encouraging’ DOR in Advanced HCC
January 20th 2024Patients with advanced hepatocellular carcinoma treated with frontline pembrolizumab plus lenvatinib showed a 3-year or more response among 35% of responders, although additional efficacy results from the trial are consistent with previous findings from the phase 3 LEAP-002 trial.
Patients With ESCC Derive Survival Benefit With Tiragolumab Plus Atezolizumab and Chemotherapy
January 20th 2024Patients with esophageal squamous cell carcinoma obtained significant survival improvements when treated with tiragolumab plus atezolizumab and chemotherapy compared with chemotherapy alone.
Adding Nivolumab to Chemo Increases OS, PFS in Previously Untreated Advanced GI Cancers
January 19th 2024Overall survival and progression-free survival improves with nivolumab plus chemotherapy compared with chemotherapy alone in the overall population and in patients with a PD-L1 CPS of 5 or greater.
HER2+ Breast Cancer May Respond to Neoadjuvant HER2 Blockade Plus Polychemotherapy
January 16th 2024Treatment with pegylated liposomal doxorubicin and cyclophosphamide in the neoadjuvant setting, followed by a taxane, in addition to trastuzumab and pertuzumab, resulted in antitumor activity in patients with HER2-positive breast cancer.